Last Update: Jun 23, 2026 A Prospective Study to Describe the Real-world Treatment Outcomes in Canadian Patients With Moderate-to-severe Hidradenitis Suppurativa Treated With secukInumab (HS-RISE) ClinicalTrials.gov Identifier: [NCT07282015](https://clinicaltrials.gov/ct2/show/NCT07282015) Novartis Reference Number:CAIN457MCA01 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice. Condition Hidradenitis Suppurativa Overall Status Recruiting Number of Participants142 Start Date Dec 12, 2025 Completion Date Feb 11, 2028 Gender All Age(s) 18 Years - 100 Years (Adult, Older Adult) ## Eligibility Criteria Inclusion Criteria: 1\. Patients must give written, signed, and dated informed consent before any information is collected and any study-related activity is performed. 2\. Adult patients at the time of informed consent signature. 3\. Patients with the diagnosis of moderate-to-severe HS, as determined by the dermatologist. 4\. Patients who have been newly prescribed secukinumab as part of routine clinical care according to the approved Canadian PM. The decision to prescribe secukinumab must be made prior to,and independent of, study participation. First treatment with secukinumab must occur no more than 7 days (≤7 days) prior to Baseline visit. 5\. Patients who can understand written and spoken Canadian English or French. Exclusion Criteria: 1\. Any medical or psychological condition in the treating physician's opinion that may prevent the patient from study participation. 2\. Patients who have any contraindications to treatment with secukinumab, as defined in the Canadian PM. 3\. Patients who have had any prior exposure to secukinumab (i.e., \\>7 days prior to the baseline visit). Canada #### Novartis Investigative Site Recruiting Winnipeg,Manitoba,R3m 3z4,Canada #### Novartis Investigative Site Recruiting Hamilton,Ontario,L8p4b4,Canada #### Novartis Investigative Site Recruiting Markham,Ontario,L3p 1x3,Canada #### Novartis Investigative Site Recruiting Mississauga,Ontario,L4w 0c2,Canada #### Novartis Investigative Site Recruiting Richmond Hill,Ontario,L4c 9m7,Canada #### Novartis Investigative Site Recruiting Sherbrooke,Quebec,J1l 0h8,Canada #### Novartis Investigative Site Recruiting Calgary,Alberta,T2j 7e1,Canada #### Novartis Investigative Site Recruiting Cobourg,Ontario,K9a 4j9,Canada #### Novartis Investigative Site Recruiting London,Ontario,N6h 5l5,Canada #### Novartis Investigative Site Recruiting Toronto,Ontario,M4e 1r7,Canada #### Novartis Investigative Site Recruiting Saint-Jérôme,Quebec,J7z 7e2,Canada #### Novartis Investigative Site Recruiting Fredericton,New Brunswick,E3b 1g9,Canada #### Novartis Investigative Site Recruiting Saskatoon,Saskatchewan,S7n0n5,Canada #### Novartis Investigative Site Recruiting Calgary,Alberta,T3e 0b2,Canada #### Novartis Investigative Site Recruiting St. John's,Newfoundland and Labrador,A1e 1v4,Canada ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: #### Novartis Pharmaceuticals Phone: - Email: -